Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients

Phase 1

Completed

• Conditions: Human Acid Sphingomyelinase Deficiency
• Interventions: Drug: Recombinant human acid sphingomyelinase

• Registration Number: NCT01722526
• Lead Sponsor: Genzyme, a Sanofi Company

Brief Summary

To evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of rhASM in adult patients with Acid Sphingomyelinase Deficiency (ASMD) following repeated-dose administration.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-11-05
• Study First Submitted QC: 2012-11-05
• Study First Posted: 2012-11-07
• Study Start: 2013-03
• Primary Completion: 2014-01
• Study Completion: 2014-01
• Status Verified: 2015-07
• Last Update Submitted: 2015-07-29
• Last Update Posted: 2015-07-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

• Patients with documented non-neuronopathic acid sphingomyelinase deficiency
• The patient has a diffusing capacity of carbon monoxide (DLco) >20% and ≤80% of the predicted normal value.
• The patient has a spleen volume ≥6 multiples of normal(MN). A partial splenectomy will be permitted if performed ≥1 year prior to Screening/Baseline and residual spleen volume is ≥6 MN.
• The patient who is receiving lipid lowering therapy should be on a stable dose and regimen of lipid-lowering therapy(ies) for at least 12 weeks prior to Screening/Baseline, with the patient expected to remain on the same dose and regimen throughout the 26-week treatment period.
• The patient who is female and of childbearing potential must have a negative serum pregnancy test for β-HCG.

Exclusion Criteria

• The patient is female and pregnant or lactating.
• The patient has a Body Mass Index(BMI)>30.
• The patient has received an investigational drug within 30 days prior to study enrollment
• The patient has a medical condition or any extenuating circumstance that may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities.
• The patient has had a major organ transplant
• ALT or AST >250 IU/L or total bilirubin >1.5 mg/dL.
• The patient is unwilling or unable to abstain from the use of alcohol for 1 day prior to and 3 days after each rhASM infusion for the duration of the study.
• The patient requires medications that may decrease rhASM
• The patient is unwilling or unable to avoid the use of medications or herbal supplements that may cause or prolong bleeding, or have potential hepatotoxicity within 10 days prior to and 3 days after liver biopsy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Recombinant human acid sphingomyelinase	Recombinant human acid sphingomyelinase	Participants will receive rhASM of an initial dose of 0.1 mg/kg, followed by several dose escalations, as tolerated, up to 3.0 mg/kg. All doses are given 2 weeks apart.

Primary Outcome Measures

Name	Time	Method
Summary of Adverse Events (AEs)	at least 26 weeks

Secondary Outcome Measures

Name	Time	Method
Pharmacodynamics as measured by liver and skin biopsies, plasma, and dried blood spot	up to 26 weeks
Pharmacokinetics as measured by peak plasma concentration (Cmax), time to peak concentration (tmax), area under curve (AUC), half life (t1/2), drug clearance (CL), and volume of distribution (Vss)	up to 26 weeks

Trial Locations

Locations (2)

Mount Sinai School of Medicine; 🇺🇸 New York, New York, United States

St. Mary's Hospital; 🇬🇧 Manchester, United Kingdom